COMP <GO>
INGN vs LLY // FORWARD P/E MULTIPLE
Inogen Inc (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: INGN 2
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: INGN
LAST: $6.86 (-5.51%) • MKT CAP: $192.7M
forward-pe
7.9x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
forward-pe
30.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INGN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INGN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.20% | 83.64% | -31.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.00% | 32.36% | -59.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.13% | 2.30% | -9.43 | LLY | /fcf-yield <GO> |
| Operating Margin | -10.20% | 40.21% | -50.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 31.90% | -24.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 45.51% | -39.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.46 | 9.29 | -7.83 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 66.6 | +2.00 | INGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 7.9x | 30.6x | -22.72 | INGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $192.7M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INGN REV | LLY REV | INGN GROSS % | LLY GROSS % | INGN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $295.3M | $65.18B | 52.2% | 83.0% | -$13.7M | $16.81B |
| FY 2024 | $278.8M | $45.04B | 55.5% | 81.3% | $2.6M | $8.82B |
| FY 2023 | $251.6M | $34.12B | — | 79.3% | -$3.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INGN // BETA —
LLY // BETA 0.51